| 高胜利,魏子秀,孙晓斐.不同剂量氯吡格雷在冠状动脉支架术后的有效性及安全性临床观察[J].济宁医学院学报,2013,(5):341-343 |
| 不同剂量氯吡格雷在冠状动脉支架术后的有效性及安全性临床观察 |
| The Comparison of effectiveness and safety between the different doses of clopidogrel in the patients after percutaneous coronary intervention |
| 投稿时间：2013-08-25 |
| DOI：10.3969/j.issn.1000-9760.2013.05.011 |
| 中文关键词: 氯吡格雷;维持剂量;心绞痛;经皮冠状动脉介入治疗 |
| 英文关键词: Clopidogrel;maintenance-dose;Angina;Percutaneous coronary intervention |
| 基金项目:山东省医药卫生科技计划项目(编号:2011HZ015) |
| 作者 | 单位 | | 高胜利 | 济南大学山东省医学科学院医学与生命科学学院, 山东济南 250062 | | 魏子秀 | 济宁医学院附属济宁市第一人民医院, 山东济宁 272011 | | 孙晓斐 | 济宁医学院附属济宁市第一人民医院, 山东济宁 272011 |
|
| 摘要点击次数: 4722 |
| 全文下载次数: 1007 |
| 中文摘要: |
| 目的 探讨冠状动脉支架术后氯吡格雷50mg/d维持剂量的有效性及安全性。方法 入选心绞痛接受冠状动脉药物洗脱支架植入术的患者119例,随机分为A组(氯吡格雷维持剂量75mg/d)和B组(氯吡格雷维持剂量50mg/d)。术前均给予300mg负荷量,术后A组给予75mg/d 维持剂量口服至少1a,B组给予75mg/d至术后第30天,术后第31天始给予50mg/d维持剂量至少1a。研究终点为随访6个月的主要心血管事件(包括死亡、支架内血栓形成、支架内再狭窄、非致死性心肌梗死、靶血管血运重建)的发生率及不良反应。结果 两组患者主要心血管事件差异无统计学意义(P>0.05);不良反应的发生率无统计学差异(P>0.05)。结论 PCI术后氯吡格雷50mg/d维持剂量可以有效地预防支架内血栓形成,不增加心血管事件及不良反应的发生。 |
| 英文摘要: |
| Objective To investigate the effectiveness and safety of 50mg/d clopidogrel in the patients after percutaneous coronary intervention(PCI).Methods A total of 119 patients with coronary heart disease(CHD)were randomly divided into two groups including group A(75mg/d)and group B(50mg/d).300 mg of clopidogrel were given to all patients on the day before PCI.75 mg of clopidogrel was given for 1 year on group A, while 150 mg of clopidogrel were given for 30 days and 50 mg of clopidogrel as maintenance-dose for at least 1 year on group B.The end points included major adverse cardiac and cerebral events(including death, stent thrombosis, in-stent restenosis, non-fatal myocardial infarction, target vessel revascularization)and other adverse reactions.Results There was no significant difference in the incidence of major cardiovascular adverse effects and other side effects between two groups(P>0.05).Conclusion The maintenance-dose of 50 mg/d clopidogrel can effectively prevent in-stent restenosis without increment of cardiovascular adverse effects. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
